0 rating

Anti-Citrullinated Protein Antibodies as a Risk Factor for Rheumatoid Arthritis

Diane van der Woude, MD, and Tom WJ Huizinga, MD, PhD
It has recently been discovered that anti-citrullinated protein antibodies (ACPA) are present in the majority of patients with rheumatoid arthritis (RA). Assays for detecting ACPA, which generally use cyclic citrullinated peptides (CCP) as targets, have been shown to have very good diagnostic and predictive characteristics, and may facilitate the identification of patients with early arthritis who need aggressive treatment.
Return to top

RELATED ARTICLES

The Economics of Rheumatoid Arthritis Management
Daniel H Solomon, MD, MPH1, and Arthur F Kavanaugh, MD2
International Journal of Advances in Rheumatology
A Question and Answer Approach to Rheumatoid Arthritis Disease Activity
Daniel Aletaha, MD, and Josef Smolen, MD
International Journal of Advances in Rheumatology
Cardiovascular Risk Factors in Rheumatoid Arthritis
Hilal Maradit Kremers, MD, MSc, Cynthia S Crowson, MS, and Sherine E Gabriel, MD, MSc
CML Rheumatology
Serum Autoantibodies in Rheumatoid Arthritis
Raimon Sanmartí, MD, Maria Victoria Hernández, MD, José A Gómez-Puerta, MD, Eduard Graell, MD, and Juan D Cañete, MD, PhD
International Journal of Advances in Rheumatology
Cardiovascular Aspects of Rheumatoid Arthritis
Michael T Nurmohamed, MD, PhD
International Journal of Advances in Rheumatology

LATEST ARTICLES